Should asymptomatic heart valve patients get surgery now? major trial aims to settle debate
NCT ID NCT03389542
First seen May 14, 2026 · Last updated Jun 22, 2026 · Updated 9 times
Summary
This study compares two approaches for people with a severe leaky heart valve (mitral regurgitation) who have no symptoms yet. Half will get early valve repair surgery, while the other half will be monitored closely every 6 months. The goal is to see which strategy leads to fewer deaths or serious heart problems over 5 years. About 424 participants are being enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEGENERATIVE MITRAL REGURGITATION (MR) DUE TO LEAFLET PROLAPSE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Amiens-Picardie
RECRUITINGAmiens, 80054, France
-
Centre Cardiologique du Nord
RECRUITINGSaint-Denis, 93200, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mitral valve repair surgery
What this could lead to
If early surgery proves better, it could establish a new standard for treating severe mitral regurgitation before symptoms appear, potentially preventing heart failure and other serious events.
What could go wrong
This is an ongoing trial with results not yet available. Surgery always carries risks like infection or complications, and watchful waiting may be equally safe for some patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.